News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
1–19
Matches
19
Sources here
11
Companies here
1
Search results Stored financial headlines

Active search

19 matching headlines

Ticker or company: ELDNMain company stories
Clear
Latest

MarketBeat Analyst action

Eledon Pharmaceuticals (NASDAQ:ELDN) Upgraded at Wall Street Zen

Wall Street Zen upgraded Eledon Pharmaceuticals (NASDAQ:ELDN) from "strong sell" to "sell," though the broader analyst consensus remains "Hold" with a $9.67 target price. The company reported a quarterly loss of $0.27 per share, missing estimates, and its shares opened at $3.54. Institutional investors hold 56.77% of the stock, with several firms recently initiating or increasing their positions.

Main company 🇺🇸 United States
Read at MarketBeat
Sharemaestro market context Trend signal active 52 weeks +36.2% ELDN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Just inNext headlines
MarketBeat Earnings Main company 🇺🇸 United States

Eledon Pharmaceuticals (NASDAQ:ELDN) Posts Quarterly Earnings Results, Misses Expectations By $0.11 EPS

Eledon Pharmaceuticals (NASDAQ:ELDN) reported a quarterly loss of $0.27 per share, missing the consensus estimate by $0.11. The stock subsequently fell 1.9% to $3.70, with a consensus "Hold" rating and an average price target of $9.67 from analysts. Institutional investors hold a significant portion …

ELDN main company
Sharemaestro market context Trend signal active 52 weeks +36.2% ELDN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Kalkine Media Balance sheet Main company 🇺🇸 United States

Eledon Pharmaceuticals Reports Q2 2026 Form 10-Q Highlighting Going Concern and Funding Challenges

Eledon Pharmaceuticals' Q2 2026 Form 10-Q filing reveals significant concerns about its ability to continue as a going concern due to ongoing operating losses and the critical need for additional financing. The company anticipates continued losses and warns that failure to secure more capital …

ELDN main company
Sharemaestro market context Trend signal active 52 weeks +36.2% ELDN stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

Investing.com UK Market update Main company 🇺🇸 United States

Form 8K Eledon Pharmaceuticals Inc For: 13 August By Investing.com

This article reports on the filing of Form 8K by Eledon Pharmaceuticals Inc. for August 13. It includes a brief mention of the company's stock symbol (ELDN) and its current performance (-4.62%), alongside general market data and other news headlines.

ELDN main company
Sharemaestro market context Trend signal active 52 weeks +36.2% ELDN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Earnings Main company 🇺🇸 United States

Eledon Pharmaceuticals (ELDN) widens Q2 loss while advancing tegoprubart to Phase 3

Eledon Pharmaceuticals reported a wider Q2 2026 net loss of $31.6 million, compared to $11.2 million a year prior, primarily due to a non-cash loss from warrant liability remeasurement. Despite this, the company is advancing its lead drug, tegoprubart, to a global Phase 3 …

ELDN main company
Sharemaestro market context Trend signal active 52 weeks +36.2% ELDN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Earnings Main company 🇺🇸 United States

Eledon Islet Study: All 12 Patients Reached Insulin Independence

Eledon Pharmaceuticals reported positive second-quarter 2026 financial results and significant clinical progress for its lead anti-CD40L antibody, tegoprubart. A successful End-of-Phase 2 FDA meeting supports a global Phase 3 kidney transplantation trial set to enroll approximately 600 patients in late 2026. Notably, an islet …

ELDN main company
Sharemaestro market context Trend signal active 52 weeks +36.2% ELDN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
GlobeNewswire Earnings Main company 🇺🇸 United States

Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Eledon Pharmaceuticals announced its second quarter 2026 financial results and key business highlights, including successful progress in its tegoprubart program. The company is on track to initiate a global Phase 3 kidney transplantation trial in late 2026, supported by positive long-term Phase 2 BESTOW …

ELDN main company
Sharemaestro market context Trend signal active 52 weeks +36.2% ELDN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Earnings Main company 🇺🇸 United States

Eledon Pharmaceuticals Inc expected to post a loss of 16 cents a share - Earnings Preview

Eledon Pharmaceuticals Inc is projected to report a loss of 16 cents per share. This information comes from an earnings preview. The full article content is behind a paywall on TradingView.

ELDN main company
Sharemaestro market context Trend signal active 52 weeks +36.2% ELDN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MarketBeat Analyst action Main company 🇺🇸 United States

Eledon Pharmaceuticals (ELDN) Expected to Release Quarterly Earnings on Thursday

Eledon Pharmaceuticals (NASDAQ:ELDN) is scheduled to release its Q2 2026 earnings after market close on Thursday, August 13th, with analysts forecasting a loss of $0.158 per share. The company previously reported a Q2 loss of $0.33 per share, missing consensus estimates. ELDN's stock recently …

ELDN main company
Sharemaestro market context Trend signal active 52 weeks +36.2% ELDN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Investing.com Earnings Main company 🇺🇸 United States

Eledon trial shows all 12 diabetes patients achieve insulin independence

Eledon Pharmaceuticals announced that all 12 patients in an investigator-initiated trial achieved insulin independence following islet cell transplantation with tegoprubart-based immunosuppression. These patients, with long-standing type 1 diabetes, no longer required exogenous insulin therapy and showed significant improvement in hemoglobin A1C levels without severe …

ELDN main company
Sharemaestro market context Trend signal active 52 weeks +36.2% ELDN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Deals and strategy Main company 🇺🇸 United States

Vanguard Capital Management (ELDN) discloses 5.05% passive stake in Eledon Pharmaceuticals

Vanguard Capital Management has disclosed a 5.05% passive ownership stake in Eledon Pharmaceuticals (ELDN) through a Schedule 13G SEC filing. This stake amounts to 3,898,446 shares, with Vanguard holding sole voting power over 481,223 shares and sole dispositive power over all 3,898,446 shares. The …

ELDN main company
Sharemaestro market context Trend signal active 52 weeks +36.2% ELDN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Eledon Pharmaceuticals Inc (ELDN) Financial Health: Profitability & Balance Sheet Analysis

Eledon Pharmaceuticals Inc (ELDN) currently holds a financial score of 5.85, ranking 311 out of 385 in the Biotechnology & Medical Research industry, indicating weak financial status and low operating efficiency. The analysis highlights that relevant financial data for Quality of Earnings, Operational Efficiency, …

ELDN main company
Sharemaestro market context Trend signal active 52 weeks +36.2% ELDN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Eledon Pharmaceuticals Inc (ELDN) Cash Flow

This article provides a detailed quarterly and annual cash flow statement for Eledon Pharmaceuticals Inc (ELDN), allowing users to evaluate the company's financial health and stability. It includes data on operating, investing, and financing cash flows, along with frequently asked questions defining these financial …

ELDN main company
Sharemaestro market context Trend signal active 52 weeks +36.2% ELDN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Eledon Pharmaceuticals Inc (ELDN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey attempts to provide a revenue breakdown for Eledon Pharmaceuticals Inc (ELDN), including business segments and regional contributions. However, it explicitly states that the relevant data have not yet been disclosed by the company, rendering the requested information unavailable. The page …

ELDN main company
Sharemaestro market context Trend signal active 52 weeks +36.2% ELDN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Market update Main company 🇺🇸 United States

Eledon Pharmaceuticals Inc (ELDN) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Eledon Pharmaceuticals Inc (ELDN), listing major individual and institutional investors and their proportional holdings. It also provides a breakdown of shareholder types, institutional shareholding over several quarters, and recent shareholder activity with specific changes in holdings. Additionally, …

ELDN main company
Sharemaestro market context Trend signal active 52 weeks +36.2% ELDN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Market update Main company 🇺🇸 United States

Eledon Pharmaceuticals Inc (ELDN) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Eledon Pharmaceuticals Inc (ELDN), detailing various volatility metrics, drawdowns, and risk-adjusted returns. It presents data points such as Beta, VaR, maximum drawdown, and Sharpe Ratios over different time frames. The information aims to help investors evaluate the …

ELDN main company
Sharemaestro market context Trend signal active 52 weeks +36.2% ELDN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Sahm Balance sheet Main company 🇺🇸 United States

Here's Why We're Watching Eledon Pharmaceuticals' (NASDAQ:ELDN) Cash Burn Situation

Eledon Pharmaceuticals (NASDAQ:ELDN) is an early-stage company that does not generate revenue, and its cash burn increased by 26% over the last year to US$69 million. Despite this, the company held US$111 million in cash as of March 2026, providing a cash runway of …

ELDN main company
Sharemaestro market context Trend signal active 52 weeks +36.2% ELDN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
GuruFocus Analyst action Main company 🇺🇸 United States

ELDN Initiated Coverage by Rodman & Renshaw -- Rating Set to Buy

Rodman & Renshaw has initiated coverage on Eledon Pharmaceuticals (ELDN) with a 'Buy' rating and a price target of $12.00, citing the company's focus on therapies targeting the CD40 Ligand pathway. Despite this positive analyst outlook, ELDN's GF Score™ of 27/100, driven by low …

ELDN main company
Sharemaestro market context Trend signal active 52 weeks +36.2% ELDN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Investing.com Canada Analyst action Main company 🇺🇸 United States

Eledon Pharmaceuticals stock initiated at Buy by Rodman & Renshaw

Rodman & Renshaw has initiated coverage on Eledon Pharmaceuticals (NASDAQ: ELDN) with a Buy rating and a $12.00 price target, citing the company's development of tegoprubart for transplant immunosuppression and type 1 diabetes. Eledon holds a strong cash position of $111 million, providing liquidity …

ELDN main company
Sharemaestro market context Trend signal active 52 weeks +36.2% ELDN stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context